US FDA Concludes Inspection at Lupin鈥檚 Goa Facility with Form-483 Observation
Lupin Ltd 路 Others (Uncategorized) 路 24 Oct 2026, 8:08 pm
US FDA Concludes Inspection at Lupin鈥檚 Goa Facility with Form-483 Observation Lupin Limited announced that the US FDA concluded an inspection at its manufacturing facility in Goa, India, conducted from 19th Oct'26 to 23rd Oct'26. The inspection closed with the issuance of a Form-483 with one observation. The company stated it will address the observation and respond to the US FDA within the stipulated timeframe, reiterating its commitment to maintaining CGMP compliance across all facilities.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
